RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at approximately $2,098,781.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00.

RxSight Stock Up 2.2 %

NASDAQ RXST opened at $49.57 on Friday. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54. The firm has a market capitalization of $1.83 billion, a P/E ratio of -48.60 and a beta of 1.20. The company has a 50-day moving average price of $52.01 and a 200-day moving average price of $53.75.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.40) EPS. As a group, equities research analysts anticipate that RxSight, Inc. will post -0.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXST. Needham & Company LLC restated a “buy” rating and set a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. BTIG Research upped their target price on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company lowered their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Oppenheimer lowered their target price on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.14.

Institutional Investors Weigh In On RxSight

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in RxSight by 21.3% in the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock worth $71,000 after acquiring an additional 207 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in RxSight by 3.2% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company’s stock worth $473,000 after acquiring an additional 242 shares in the last quarter. RiverPark Advisors LLC increased its holdings in RxSight by 9.6% in the 2nd quarter. RiverPark Advisors LLC now owns 3,379 shares of the company’s stock worth $203,000 after acquiring an additional 297 shares in the last quarter. CWM LLC increased its holdings in RxSight by 727.5% in the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in RxSight by 5.0% in the 2nd quarter. Arizona State Retirement System now owns 7,765 shares of the company’s stock worth $467,000 after acquiring an additional 373 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.